Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

D2 Dopamine Receptor

Predominantly inhibitory dopamine receptor; antagonism is the antipsychotic mechanism, agonism is the antiparkinsonian mechanism. Targeted indirectly by L-DOPA precursors and partial-agonist plants.

31 drugs act here3 plants reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on D2 Dopamine Receptor

These medications have D2 Dopamine Receptor among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

AmisulprideAmoxapineAripiprazoleAsenapineBrexpiprazoleCarbidopa-LevodopaCariprazineChlorpromazineClozapineDextroamphetamineDopamineFluphenazineHaloperidolLisdexamfetamineLurasidoneMethamphetamineMethylphenidateMetoclopramideMixed Amphetamine SaltsOlanzapinePaliperidonePramipexoleProchlorperazinePromethazineQuetiapineRisperidoneRopiniroleRotigotineTrimethobenzamideTrimipramineZiprasidone

Botanical connections

Plants whose compounds act on D2 Dopamine Receptor

Each plant below contains a named compound documented to act on D2 Dopamine Receptor. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

Blue Lotus
E
  • NuciferineAporphine alkaloid

    D2 receptor antagonist with 5-HT1A/5-HT2A modulation — receptor-binding profile resembles atypical antipsychotics in vitro.

  • Aporphine alkaloids (apomorphine traces)Aporphine alkaloid

    Trace dopaminergic alkaloids contributing to subjective effects.

Chasteberry
A
  • Diterpene fraction (rotundifuran)labdane diterpene

    Dopamine-D2 receptor agonist activity in the anterior pituitary — reduces prolactin secretion. The principal mechanism for the well-documented effects on PMS, mastalgia, and latent hyperprolactinemia.

Mucuna / Velvet Bean
B
  • L-DOPACatecholamine precursor (amino acid)

    Direct levodopa — chemically identical to the prescription drug. After hepatic + CNS decarboxylation, L-DOPA becomes dopamine, raising D1/D2 activity. The reason Mucuna is functionally a Parkinson’s drug, not a supplement.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.